Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17601809 | 1.00 | MAOB (0.52) | MAOBS1PR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16914929 | 0.88 | MAOB (0.52) | MAOBS1PR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16915177 | 0.88 | MAOB (0.52) | MAOBS1PR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16269498 | 0.82 | MAOB (0.60) | MAOBS1PR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16269703 | 0.82 | MAOB (0.53) | MAOBS1PR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16269783 | 0.82 | MAOB (0.60) | MAOBS1PR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16277048 | 0.81 | MAOB (0.58) | MAOBS1PR1RAB9APPARGPPARA | |
| SCHEMBL16914904 | 0.81 | S1PR1 (0.61) | MAOBS1PR1SMN1; SMN2PPARGPPARA | |
| SCHEMBL17601795 | 0.81 | S1PR1 (0.61) | MAOBS1PR1SMN1; SMN2PPARGPPARA | |
| SCHEMBL17601801 | 0.81 | S1PR1 (0.60) | MAOBS1PR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083380-A1 | OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA | OAT, CYP11B2, CYP11B1 | MAOB 220/4885S1PR1 1228/4885NPC1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.